ArticleACS medicinal chemistry letters2025
Structural Optimization of Antifungal Peptoids targeting
Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections pose a significant global health threat, with rising antifungal resistance, high mortality rates, and limited treatment options. Peptoids offer a promising alternative to traditional antifungal agents due to their enhanced stability and bioavailability. This study sought to optimize the antifungal peptoid RMG9-11 through an iterative structure-activity relationship (SAR) approach, focusing on improving antifungal potency while minimizing cytotoxicity. A total of 50 derivatives were synthesized across four rounds of modification, incorporating diverse structural alterations. Several derivatives demonstrated enhanced antifungal activity, with five top-performing compounds exhibiting improved selectivity ratios and good efficacy against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.